Nuclear Receptor ROR: A Potential Drug Target and Biomarker (P38456)

Target Name: Nuclear Receptor ROR

NCBI ID: P38456

Nuclear Receptor ROR

Other Name(s): Nuclear Receptor ROR | ROR

Nuclear Receptor ROR: A Potential Drug Target and Biomarker

Nuclear receptors are a family of transmembrane proteins that play a crucial role in intracellular signaling. These receptors are involved in various physiological processes, including cell growth, differentiation, and metabolism. One subtype of nuclear receptor, known as ROR (nonspecified subtype), has been identified as a potential drug target and biomarker for various diseases.

ROR is a nuclear receptor that is expressed in various tissues and cells throughout the body. It is a G protein-coupled receptor (GPCR), which means that it interacts with intracellular signaling molecules, such as G protein-coupled receptors. GPCR signaling pathways are involved in various physiological processes, including cell signaling, angiogenesis, and inflammation.

ROR is involved in several signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and metabolism. This pathway is a well-established target for many drugs, including anti-cancer drugs. By activating TGF-β signaling, ROR can promote cell proliferation and differentiate into various cell types.

In addition to its role in TGF-β signaling, ROR is also involved in the Wnt signaling pathway. Wnt signaling is involved in cell-cell signaling, including the development and maintenance of tissues and organs. ROR has been shown to play a role in regulating Wnt signaling in various tissues, including the placenta and fetal brain.

ROR has also been shown to be involved in the Hedgehog signaling pathway. Hedgehog signaling is involved in cell-extracellular matrix (ECM) signaling, which is involved in tissue development and regeneration. ROR has been shown to play a role in regulating Hedgehog signaling in various tissues, including the liver and pancreas.

GPCR signaling pathways are often targeted by drugs because of their potential therapeutic benefits. Many drugs that are currently in use target GPCR signaling pathways, including anti-cancer drugs,尾-cell antitumor drugs, and neurodegenerative drugs. By targeting ROR, these drugs can inhibit the effects of these signaling pathways and potentially improve treatment outcomes.

In addition to its potential therapeutic applications, ROR is also a potential biomarker for various diseases. The ROR gene has been shown to be involved in various physiological processes, including cell growth, differentiation, and metabolism. This suggests that ROR may be a useful biomarker for diseases that involve these processes, such as cancer, neurodegenerative diseases, and diseases that involve cellular signaling pathways, such as TGF-β and Wnt signaling.

In conclusion, Nuclear Receptor ROR is a potential drug target and biomarker for various diseases. Its involvement in various signaling pathways, including TGF-β, Wnt, and Hedgehog signaling pathways, makes it an attractive target for small molecules that can inhibit its effects. Further research is needed to fully understand the role of ROR in various physiological processes and to develop effective treatments for diseases that involve these processes.

Protein Name: Nuclear Receptor ROR (nonspecified Subtype)

The "Nuclear Receptor ROR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Nuclear Receptor ROR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets